Menu Search
Equities

Bausch Health Companies Inc

BVF:BER

Bausch Health Companies Inc

Actions
  • Price (EUR)6.88
  • Today's Change0.146 / 2.17%
  • Shares traded0.00
  • 1 Year change-66.78%
  • Beta--
Data delayed at least 15 minutes, as of Mar 30 2023 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company develops, manufactures, and markets, primarily in the therapeutic areas of eye health, gastroenterology (GI), and dermatology, a range of branded, generic and branded generic pharmaceuticals, over the counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. The Company operates through five segments: Bausch + Lomb, Salix, International, Solta Medical, and Diversified Products. The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical, and Ophthalmic Pharmaceuticals products. The Salix segment consists of sales in the United States of gastrointestinal (GI) products. The Solta Medical segment consists of global sales of Solta aesthetic medical devices.

  • Revenue in CAD (TTM)11.01bn
  • Net income in CAD-304.99m
  • Incorporated2013
  • Employees19.90k
  • Location
    Bausch Health Companies Inc2150 Saint-Elzear Blvd WLAVAL H7L 4A8CanadaCAN
  • Phone+1 (514) 744-6792
  • Fax+1 (514) 744-6792
  • Websitehttps://www.bauschhealth.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.